Introduction
Antimicrobial resistance will probably complicate future treatment of bone infection, treatment of which requires local and systemic antibiotics and often several surgical interventions. The non-degradable polymethylmethacrylate beads which are used currently as antibiotic carriers require operative removal and may induce resistant bacteria. 1 We aimed to address this increasing problem by combining an antimicrobial peptide (AMP) of human origin (hLF1-11) with biodegradable carriers-which obviates the need for operative removaland analysing its availability and release. These carriers, which consist of (a combination of) calcium-phosphate ceramics, e.g. tricalcium phosphate, Ca 3 (PO 4 ) 2 , are slowly replaced by ingrowing bone after implantation. 2 AMPs form a novel class of antimicrobial agents of natural origin that have been identified in virtually all forms of life as part of the antimicrobial defence system. These positively charged peptides kill by forming pores in the negatively charged bacterial cell-membrane and targeting intracellular organelles, without development of resistance. 3 Moreover, they seem to have an immunomodulating effect, killing microorganisms at lower concentrations in vivo (ng/mL) than in vitro (µg/mL). 4, 5 
Materials and methods
Peptide hLF1-11-peptide (GRRRRSVQWCA, 1375 Da) was manufactured by solid-phase peptide synthesis using Fmoc (9-fluorenyl-methoxycarbonyl) chemistry as described previously. 6 Reanalysis of peak fractions by reversed phase HPLC resulted in one major peak revealing at least 90% purity. The authenticity was confirmed by electrospray-ionization quadrupole-time-of-flight mass-spectrometry (Q-TOF MS, Micromass Inc., Manchester, UK). Thermal stability in solution, adhesion to polystyrene and solubility were tested as described previously. 7 
Release experiment
After mixing cement powder and liquid containing 5 mg hLF1-11 per gram of powder (liquid/powder ratio according to the manufacturer), cylindrical specimens hardened overnight at 37°C in 6 × 5 mm moulds. Specimens were immersed in 500 µL of dH 2 O and kept in sealed polystyrene 48-well plates (Costar) at room temperature on a shaking device (180 rpm). The water was replaced at regular intervals: 30, 90 and 180 min on day 1 and then 24 hourly for 7 days (cements) or 3 days (granules) and stored at -20°C.
After production and after release, three specimens per group were finely ground and suspended in 5 mL dH 2 O containing 1 M NaCl and the initial and residual hLF1-11 were determined. The hLF1-11 remaining in the vessel after lyophilization of the granules was also determined.
The hLF1-11 concentration was measured using a bicinchoninic acid protein assay (Pierce, Rockford, IL, USA) and read at 540 nm (Bio-Rad) (hLF1-11 serial dilutions were used as a reference, the detection limit was 2.5 µg). Accuracy of the assay was calculated as 6.5% (mean error of true value), precision 3.5% (coefficient of variance). Control samples without hLF1-11 were used for background correction. The authenticity of the hLF1-11 of the first day release samples was analysed by Q-TOF MS and sequencing of the 1375 Da peak in one of the samples.
Antimicrobial activity
Samples of 500 µL release medium (taken after 24 h) were lyophilized (without carrier material) and 10 6 cfu of an MRSA clinical isolate (ATCC BAA-811) in PBS containing 0.01% Brain Heart Infusion was added. After 60 min at 37°C, these were plated on blood agar (n = 6), and colonies were counted after 18 h at 37°C. The percentage of killing was calculated: [1 -(cfu in sample/cfu in control)] × 100% (>90% was considered active). Samples without hLF1-11 were used as controls, samples from the first day were used because these all contained adequate amounts of peptide.
Results
Tests of hLF1-11 confirmed stability at 37°C in water for 26 weeks, solubility up to 150 mg/mL and no adhesion to polystyrene. Sample weight showed only a small variation (<0.01 g in samples of 0.150 g). Table 1 shows the amount of hLF1-11 that was initially available for dissociation, the quantity that was actually released from the carrier, and the part that was left in the carrier. From the cements, less hLF1-11 was extractable (2.65-3.43 mg/g) than had been incorporated (5 mg/g). For the granules, the amount of available peptide varied (1.5 g-4.6 mg/g), the rest was recovered from the vessel after lyophilization.
All cements displayed a sustained release profile for several days, with Biobon, Biofil and Chronos releasing significantly more hLF1-11 than the three other cements (Figure 1 ). All granules had burst release profiles in the first day only; Bicalphos, Bonesave and Vitoss released significantly more peptide than the other three granule types (not shown).
After release, a 1375 Da peak on MS-QTOF of the correct aminoacid sequence confirmed the integrity of hLF1-11 (control samples had no 1375 Da peak). The antimicrobial activity was >90% in nine of 12 carriers (Table 1) .
Discussion
Low systemic toxicity and high local drug concentrations are the main advantages of local antibiotic delivery systems. These can be used both for treatment of chronic bone infection, requiring prolonged high antibiotic concentrations and for prevention, in which a short duration local antibiotic peak concentration may suffice. 8 Using methods described by Kühn, adapted for biodegradable specimens, we determined the available hLF1-11 in samples before and after release. 9 Not all hLF1-11 added to cement was available for extraction, even after fine grinding and adding high salt concentra- Table 1 . hLF1-11 released by the carriers and antimicrobial activity against MRSA The amount of hLF1-11 available immediately after production (biologically available) and after the release experiment (extracted after release) was determined by fine grinding and addition of 1 M NaCl. The values represent the mean ± S.D. from three experiments, totalling at least 12 samples per carrier-material. Sterile cultures were considered 99% killing, the detection limit. tions to decrease charge-dependent binding. This suggests that part of the hLF1-11 strongly binds to the hardening cement leading to sequestration and unavailability for release, but it might still become available after osteoclastic resorption. A variable amount of hLF1-11 attached to the granules during lyophilization, and the rest was detected in the coating vessel. Highporosity granules (Vitoss) bound most hLF1-11 indicating that the surface area of the carrier material might determine the loading capacity.
Thus, two different release profiles were observed in this study, which support a two-phase explanation of the release process. The initial burst-release is predominantly determined by the release of the drug from the surface of the carrier; the second phase shows the more gradual diffusion of the drug from deeper layers, determined by the porosity of the carrier. 9 The hLF1-11 released in the first day was active in nine of the 12 materials. Of these, Chronos was the highest releasing cement-type and Vitoss the highest releasing granule-type ( Table 1 ). The amount of hLF1-11 released may be relevant in vivo, as Nibbering and co-workers demonstrated that hLF1-11 concentrations as low as 0.1 ng/mL kill MRSA in vivo.
Limitations of this study can be found in the extrapolation of the in vitro results to in vivo concentrations in bone and surrounding tissues. Instead of using simulated body fluid as the release medium, the experiment was carried out using small volumes of water. This allowed the use of a simple protein assay for the detection of hLF1-11. Disadvantages of this method are: (i) pH and ionic content were different from the in vivo situation, (ii) proteases that could degrade the hLF1-11 were not present, (iii) any positive interaction of AMP with the adaptive immune system could not be included. 5 The strength of in vitro release studies of this kind lies in a qualitative comparison of different carrier materials, allowing the identification of the most suitable materials for in vivo testing. In spite of the in vitro shortcomings, a positive correlation between in vivo and in vitro results has been reported by several authors. 10 To conclude, in nine of the 12 combinations, basic requirements for designing a drug delivery system (controlled release of an active substance) have been met. 8 At present, investigations using animal models to study the in vivo efficacy of AMP-releasing drug delivery systems are under way.
